ChemoCentryx

Our Phase III ADVOCATE trial evaluating the safety and efficacy of avacopan in patients with ANCA Vasculitis has completed enrollment. Top-line data expected in Q4 2019.

Clinical study evaluating CCX140 in Focal Segmental Glomerulosclerosis (FSGS) with and without Nephrotic Syndrome – Now Enrolling.

ChemoCentryx Employees Highlight Vasculitis Awareness Month #VAM2019
ChemoCentryx proudly supports the vasculitis community in searching for novel therapies to address the high unmet needs in ANCA-associated vasculitis. Follow us & learn of the important strides we are making.

People Deserve Better Medicine

At ChemoCentryx, we believe our patients deserve more than the standard of care available today. So, we are developing our broad portfolio of new medicines using a novel approach to better provide patients with safe, convenient and more effective therapies.

We are developing tomorrow’s standard of care.

Learn more

Not Just a Longer Life, a Better Life

People suffering from serious medical conditions want more than incremental improvements. Like all of us, they want to live longer, more enjoyable lives. That’s why when others say, “This is the best we can do,” we say, “We can do better.”

We are developing a better way to treat disease.

Share our passion

A New Approach. A Better Approach.

Our vision is simple. We believe that a targeted biological system—the chemoattractant network—is the key to longer, better lives for thousands of people suffering from serious disease. And we intend to deliver that quality of life to patients through a passion for great science.

Our great science leads to great medicine.